User:Nabhaj

Dr Nabil Hajji (NH) got his PhD in Molecular Oncology at Seville University. He held his first postdoctoral appointment at Macarena hospital, Seville. Subsequently, he held postdoctoral appointments at Karolinska Institute at Stockholm, Sweden. NH also got a cancer research UK research fellow position at the Institute of Cancer Studies at Birmingham University and at the Institute of Cell and Molecular Science at Barts and the London. Currently NH is lecturer in epigenetics and translational oncology with a strong expertise and track record in the mechanisms of epigenetics alteration in cancer(e.g colorectal cancer), mitochondrial and apoptosis pathways. NH over the last few years has established the mechanism behind classical anticancer treatment resistance of several types of cancer, which is related to deficiencies in the epigenetic mechanism that control apoptotic machinery. NH focuses on epigenetics and drug resistance research. He examines how epigenetic alteration leads to tumours resistance to chemotherapy and used approaches to improving treatment by overcoming drug resistance. NH research area of interest and expertise also includes different aspects of epigenetic alterations as biomarkers of drug resistance.

https://scholar.google.co.uk/citations?user=3EAaRykAAAAJ&hl=en